Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Onco-Innovations Ltd. ( (TSE:ONCO) ).
Onco-Innovations Limited announced a significant study by the co-founders of its subsidiary, Inka Health Corp., which advances the real-world applicability of lung cancer clinical trial outcomes. The study, published in medRxiv, demonstrates a novel approach to aligning clinical trial results with real-world patient outcomes, particularly for non-small cell lung cancer. By incorporating external data and expert knowledge, the study’s model achieved a near-perfect match with real-world outcomes, highlighting its potential to improve clinical decision-making and expand patient access to innovative therapies. This advancement is crucial as it addresses the challenge of translating trial results to diverse populations, offering a scalable and scientifically rigorous methodology that could influence regulatory approvals and healthcare practices.
More about Onco-Innovations Ltd.
Onco-Innovations Limited operates in the healthcare industry, focusing on cancer research and drug development. Through its subsidiary, Inka Health Corp., the company leverages advanced real-world analytics to enhance the applicability of clinical trial outcomes to diverse patient populations globally.
Average Trading Volume: 78,983
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.